The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

Johnson and Johnson Nov. 12 filed a lawsuit against the Department of Health and Human Services and the Health Resources and ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Johnson & Johnson’s rebate model aims to address misuse of 340B Program. HRSA’s threats of penalties led J&J to halt the ...

Premier alleges the Health Resources and Services Administration lacks authority to enforce a policy restricting how 340B ...

“HRSA’s attempts to bar J&J from bringing transparency to the 340B Program through implementation of the Rebate Model are ...

The latter requirement applies to the item or service regardless of whether it is listed in the current HRSA-supported guidelines. In informal FAQs issued over the years, the departments have stated ...

Leidos announced a new contract to modernize the Organ Procurement and Transplant Network (OPTN), a critical system that delivers vital organ transplant information to patients, donors, and healthcare ...